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Objective: The polyglutamine diseases, including Huntington’s disease (HD) and multiple spinocerebellar ataxias
(SCAs), are among the commonest hereditary neurodegenerative diseases. They are caused by expanded CAG
tracts, encoding glutamine, in different genes. Longer CAG repeat tracts are associated with earlier ages at onset,
but this does not account for all of the difference, and the existence of additional genetic modifying factors has
been suggested in these diseases. A recent genome-wide association study (GWAS) in HD found association
between age at onset and genetic variants in DNA repair pathways, and we therefore tested whether the modifying
effects of variants in DNA repair genes have wider effects in the polyglutamine diseases.
Methods: We assembled an independent cohort of 1,462 subjects with HD and polyglutamine SCAs, and genotyped
single-nucleotide polymorphisms (SNPs) selected from the most significant hits in the HD study.
Results: In the analysis of DNA repair genes as a group, we found the most significant association with age at onset
when grouping all polyglutamine diseases (HD1SCAs; p 5 1.43 3 10–5). In individual SNP analysis, we found signifi-
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cant associations for rs3512 in FAN1 with HD1SCAs (p 5 1.52 3 10–5) and all SCAs (p 5 2.22 3 10–4) and
rs1805323 in PMS2 with HD1SCAs (p 5 3.14 3 10–5), all in the same direction as in the HD GWAS.
Interpretation: We show that DNA repair genes significantly modify age at onset in HD and SCAs, suggesting a
common pathogenic mechanism, which could operate through the observed somatic expansion of repeats that can
be modulated by genetic manipulation of DNA repair in disease models. This offers novel therapeutic opportunities
in multiple diseases.
ANN NEUROL 2016;79:983–990
Over 30 human diseases are caused by expansion ofunstable microsatellite sequences.1 Nine contain
repeats that encode glutamine, usually referred to as the
polyglutamine diseases (Table 1), and have common fea-
tures, including autosomal-dominant inheritance (except
X-linked spinal and bulbar muscular atrophy), genetic
anticipation, neuronal involvement, and intracellular
inclusions containing the cognate polyglutamine protein.
The phenotypes vary, potentially reflecting differences in
the temporal and regional expression and protein context
of the disease-causing expansions2 (see Table 1). There
are currently no disease-modifying treatments for these
devastating conditions.
In the polyglutamine diseases, longer CAG repeat
tracts lead to earlier age at onset (AAO), though the rela-
tionship varies between diseases (see Table 1).3,4 Not all
of the difference in AAO is accounted for by CAG repeat
length, and in Huntington’s disease (HD)4 and at least
spinocerebellar ataxia (SCA) types 2 and 3,5 a substantial
portion of this residual variance is heritable, suggesting
the existence of additional modifying factors within the
genome. The Genetic Modifiers of Huntington’s Disease
(GeM-HD) genome-wide association study (GWAS)6
found two genome-wide loci associated with age at
motor onset in HD on chromosomes 15 and 8, with
two independent signals at the same locus on chromo-
some 15. A few SCA genetic modifiers have been pro-
posed3,5,7–9 and no GWAS have been reported.
Genetic anticipation in these diseases occurs
because the repeats are meiotically unstable and tend to
expand over successive generations; most also show
tissue-specific somatic instability10 (see Table 1). In HD,
somatic instability is expansion-biased and age- depend-
ent, with larger tracts more susceptible to expansion.11,12
It occurs in postmitotic neurons and is prominent in
striatum and cortex, tissues particularly affected in HD.13
Somatic instability has been linked to disease onset and
progression in both human14 and mouse HD studies,15
and decreasing somatic expansion in HD model mice
delays phenotype progression.16 Many of the principles
of somatic instability in HD extend to SCAs.1,10 Somatic
instability12,17,18 has been attributed to the actions of
DNA repair proteins, and as well as the individually
associated variants, the GeM-HD GWAS found signifi-
cant association between age at motor onset and several
DNA repair pathways.6 These GeM-HD GWAS find-
ings, along with evidence for somatic instability in other
polyglutamine diseases (see Table 1), led us to hypothe-
size that variants in DNA repair genes might modify
AAO in all polyglutamine diseases.
In this report, we demonstrate significant associa-
tions between variants in genes involved in DNA repair
pathways and the AAO of polyglutamine diseases as a
group as well as with some polyglutamine diseases
individually.
Patients and Methods
Patients
Subject cohorts were gathered from the Neurogenetics Unit and
Ataxia Center of the National Hospital for Neurology and Neu-
rosurgery (London, UK), TRACK-HD (Europe),19 SPATAX
network (France), the University of Athens Medical School/Egi-
nition Hospital (Athens, Greece), the National Institute of Neu-
rology and Neurosurgery, Manuel Velasco Suarez (Mexico), and
the University of Azores (Ponta Delgada, Portugal; Table 2). All
subjects with polyglutamine diseases seen at any of the collabo-
rators sites and willing to participate in research were enrolled
regardless of their CAG repeat size or AAO. All studies were
approved by local ethics committees, and all subjects gave writ-
ten informed consent. For this study, we gathered samples and
data for HD and SCAs 1, 2, 3, 6, 7, and 17; very few
dentatorubral-pallidoluysian atrophy (DRPLA) and spinal and
bulbar muscular atrophy (SBMA) samples were available to us,
so these diseases were not included. AAO and CAG repeat size
was available for 1,462 patients (see Table 2). Given the varied
phenotypes of polyglutamine diseases, motor onset (HD) or
onset of the first progressive symptom as reported by the
patient was used to determine AAO throughout all cohorts.
Given the small number of patients, SCA17 was only consid-
ered in the combined SCA analysis.
Single-Nucleotide Polymorphism Selection
Criteria and Genotyping
Single-nucleotide polymorphisms (SNPs) were selected from the
most significant genes (gene-wide, p < 0.1) in the “DNA repair
pathway cluster” from the GeM-HD analysis (listed in Table
S4 of the GeM-HD article).6 SNPs from RRM2B and UBR5
were added to this list because they are both members of
GO:6281 “DNA Repair” (which, although nominally signifi-
cant in GeM, did not reach q < 0.05 and was therefore not
used to create the pathway cluster), both lie within a genome-
wide significant association peak in GeM-HD, and both have
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significant gene-wide p values (see Table S5 of the GeM-HD
article).6 For each gene, the most significant SNP was selected,
along with a small number of proxy SNPs in close LD (r2 >
0.8) with the most significant SNP that also showed association
in GeM-HD. Where possible, these proxy SNPs were chosen to
have functional annotation (http://browser.1000genomes.org/
index.html: accessed 12/6/14). If a gene contained two inde-
pendent significant signals in GeM-HD (e.g., FAN1), then the
lead SNP for the second signal was included. Note that this
selection procedure is not intended to give comprehensive
TABLE 2. Cohort Characteristics
Cohort Disease
HD SCA1 SCA2 SCA3 SCA6 SCA7 SCA17 Total
Athens, Greece 351 0 0 0 0 0 0 351
Azores, Portugal 0 0 0 91 0 0 0 91
London, UK 0 30 66 45 69 7 1 218
Mexico 0 0 113 0 0 66 6 185
SPATAX, France 0 147 115 261 0 0 0 523
TRACK-HD,
Europe
94 0 0 0 0 0 0 94
Total 445 177 294 397 69 73 7 1,462
% M 49.4 54.2 48.6a 52.6 60.9 56.2 85.7 51.8a
Mean AAO 6
SD (range)
45 6 12.1
(6–82)
37 6 10.5
(16–65)
33 6 12.9
(8–73)
39 6 11.6
(9–74)
57 6 10.5
(18–76)
35 6 17.6
(5–84)
30 6 13.4
(8–44)
Mean (CAG)n
length 6 SD
(range)
44 6 5.0
(37–92)
48 6 5.3
(39–66)
42 6 4.5
(33–64)
71 6 4.4
(50–82)
22 6 0.9
(21–26)
48 6 11.1
(36–100)
51 6 6.4
(42–58)
aOne subject had no sex information.
HD 5 Huntington’s disease; SCA 5 spinocerebellar ataxia; % M 5 percentage of males; AAO 5 age at onset; SD 5 standard
deviation.
TABLE 1. Characteristics of the Polyglutamine Diseases
Repeat
Disorder
Gene Prevalence Variance in AAO
Explained by
Repeat Length
Normal
Range
Pathogenic
Range
Somatic
Instability
HD HTT 3–10 50–60% (40–60%) 6–35 40–121 Yes
SCA1 ATXN1 0.16 64–76% (no detected
heritable component)
6–38 45–83 Yes
SCA2 ATXN2 0.2 50–80% (17–59%) 15–31 33–500 Yes
SCA3 ATXN3 0.4 45–80% (46%) 12–44 52–87 Yes
SCA6 CACNA1A 0.04 26–52% (no detected
heritable component)
4–18 20–33 Unknown
SCA7 ATXN7 0.12 71–88% (no detected
heritable component)
3–19 37–460 Yes
SCA17 TBP <0.02 Unknown 25–40 49–66 Unknown
DRPLA ATN1 0.005–0.04 50–68% 6–35 48–93 Yes
SBMA AR 0.65–2.00 29% 9–34 38–72 Yes
Epidemiology and CAG repeat ranges of polyglutamine diseases. Prevalence is given/100,000 European population. AAO 5 age at
onset; HD 5 Huntington’s disease; SCA 5 spinocerebellar ataxia; DRPLA 5 dentatorubral-pallidoluysian atrophy; SBMA 5 spi-
nal and bulbar muscular atrophy.
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coverage of the genes in question, but instead to highlight
SNPs likely to be disease relevant. To guard against the effects
of population stratification, SNPs were removed from the anal-
ysis if they had a Hardy-Weinberg p value <0.001 in the whole
data set. These procedures yielded 22 genotyped SNPs with
success rates ranging from 94.2% to 98%, as described in Sup-
plementary Table 1.
SNP genotyping was performed using custom KASP assays
at LGC Genomics (Hertfordshire, UK). Gene-level sense sequen-
ces were used to design SNP assays (see Supplementary Table 2).
The assays for several SNPs were designed in reverse orientation
to the chromosome (rs4150407, rs1805323, rs1037700,
rs1037699, rs3512, and rs20579). For this reason, for all SNPs in
reverse orientation to the chromosome (rs4150407, rs1805323,
rs1037700, rs1037699, rs3512, and rs20579), genotypes result-
ing from these KASP assays will be complementary to those using
HGVS nomenclature. This is reflected in Supplementary Table 3,
where the minor allele for these SNPs differs from GeM-HD,6
but corresponds to the same allele.
Statistical Analyses
AAOs for the various diseases were corrected for repeat length
using a similar method to the GeM-HD GWAS.6 A linear
regression was performed for each disease separately of ln(AAO)
on expanded repeat length. Regression parameters are given in
Table 3. These parameters were used to construct an expected
value of AAO for each individual, based on their repeat length,
which was subtracted from their actual AAO to give a residual.
Association of each SNP with AAO was tested by performing a
linear regression of these residuals on the number of minor
alleles in the genotype in PLINK.20 The effect of gender on
AAO (after accounting for CAG length) was also tested. Since
this was nonsignificant for all disorders (results not shown),
gender was not included in the calculation of residuals.
The primary analysis in this report tested whether there
was an overall association of AAO across all 22 SNPs. This was
done by combining the association p values for each SNP using
Brown’s method.21 Essentially, this is Fisher’s method for com-
bining p values corrected for linkage disequilibrium between
SNPs. The primary analysis used one-sided p values for associa-
tion in the same direction as that observed in GeM-HD. In
order to assess the overall directionality of the associations, we
compared the significance to that obtained from a similar anal-
ysis using two-sided p values. The analyses were performed on
eight disease groups: all polyglutamine diseases (HD1SCAs),
HD, all SCAs, SCA1, SCA2, SCA3, SCA6, and SCA7. p values
were Bonferroni corrected for eight tests—this is conservative
given that the disease groups are not independent. Individual
SNPs significantly associated with AAO in each disease group
were also noted. Because of small sample size, SCA17 was not
analyzed independently, but was included in the analyses of all
SCAs and HD1SCAs.
Results
In the primary analysis, which tested the overall effect of
all 22 SNPs on AAO, significant associations (after Bon-
ferroni correction for eight tests) were observed for
HD1SCAs (p 5 1.43 3 10–5), HD (p 5 0.00194), all
SCAs (p 5 0.00107), SCA2 (p 5 0.00350), and SCA6
(p 5 0.00162). The increased significance of these asso-
ciations compared to an undirected test using two-sided
SNP p values (see supplementary Table 3) indicates con-
cordance in the direction of effects across SNPs between
these samples and GeM-HD.6 In particular, the observed
association with HD is a convincing replication of the
GeM-HD results in an independent sample.
As a secondary analysis, individual SNP associations
were examined. Three of these were significant after Bon-
ferroni correction for eight disease combinations and 22
SNPs (Table 4 and Supplementary Table 4): rs3512 in
FAN1 with all SCAs and HD1SCAs and rs1805323 in
PMS2 with HD1SCAs. Each association was in the
same direction as in GeM-HD.6 We did not replicate
the most significant signal in GeM-HD, rs146353869
(p 5 4.30 3 10–20, associated with 6 years earlier age at
motor onset of HD). This is likely due to our sample
being much smaller than GeM-HD and thus less well
powered to find associations with SNPs with relatively
low-frequency minor allele frequency (MAF) such as
rs146353869 (MAF 5 0.017). However, rs3512, the
most significant individual SNP in this study, indexes the
second significant chromosome 15 signal in GeM-HD
(p 5 5.28 3 10–13, associated with 1.4 years later onset
of HD), and is in the 30UTR (untranslated region) of
FAN1. Three SNPs (rs1037700, rs5893603, and
rs16869352) were found to be in high LD (r2 > 0.8) in
our sample with more significant SNPs from GeM-HD.
Removing these SNPs reduced the significance of the
multi-SNP associations with SCA2 and SCA6, although
TABLE 3. Effects of Repeat Length of the
Expanded Allele on the Age at Onset
Disease Sample
N
A B p
HD 445 6.119939 20.052966 <2e-16
SCA1 177 5.682974 20.043694 <2e-16
SCA2 294 5.799343 20.056682 <2e-16
SCA3 397 7.137211 20.049477 <2e-16
SCA6 69 5.96740 20.08686 0.00268
SCA7 73 4.643231 20.026023 2.94e-5
SCA17 7 2.38659 0.01716 0.70
Results of fitting a linear regression ln(AAO) 5 A 1
B*(CAG)n. p value refers to the significance of the regres-
sion parameter (B) indexing the effect of repeat length.
HD 5 Huntington’s disease; SCA 5 spinocerebellar ataxia.
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these remained nominally significant (see Supplementary
Table 3). Finally (see Supplementary Table 3), all the sig-
nificant multi-SNP associations from the primary analysis
remained significant after removing the most significant
single SNP (rs3512), suggesting that the signal enrich-
ment is not being driven by a single SNP.
To visualize the combined effect of our SNPs on
residual AAO a polygenic “age at onset score” was
derived, defined as the sum of the number of minor
alleles at each locus weighted by their effect size in GeM-
HD (note that negative scores here correspond to earlier
AAO). The residual AAO for each quartile of this risk
score was plotted in Figure 2. As expected, there was a
positive correlation between residual AAO in our data
and increasing age at onset score, although the effect was
small—the score accounts for approximately 1% of the
variance of residual AAO.
Discussion
Our data implicate a common mechanism by which
genetic variation in DNA repair pathways underlies age at
onset of disease in multiple polyglutamine diseases. Altera-
tions in DNA repair pathways could predispose to earlier
onset by interacting with polyglutamine etiology at various
levels. Rare loss-of-function variants in DNA repair genes
cause multiple recessive ataxias22; ATM encodes a master
regulator of DNA repair following double-strand breaks,23
PNPK encodes a DNA-specific kinase that facilitates DNA
repair,24 APTX encodes a protein that interacts with
PARP1 to mediate single strand DNA breaks,25 and muta-
tions in TDP1 also give defects in single-strand break
repair.26 The mechanisms by which neurodegeneration
and ataxia result from these losses of function are not con-
clusively established, but there is substantial evidence for
the fine control exercised by ATM being critical in cell divi-
sion and cell death pathways, which could lead to neuronal
loss.27 However, it is notable that none of the genes associ-
ated with recessive ataxia syndromes were identified to con-
tain HD-related variants in HD-GeM.6
Repetitive DNA sequences can form unusual sec-
ondary structures28 to which DNA mismatch repair pro-
teins bind and, in the process of repair, cause somatic
instability (often expansion) of the CAG repeats. A num-
ber of enzymes with the ability to nick DNA and there-
fore necessitate DNA repair are known to promote CAG
expansion and both somatic expansion and HD-related
phenotypes are ameliorated in mouse models by manipu-
lating genes associated with DNA repair.15,29–32 Crit-
ically, delay in phenotype onset in HD mice was recently
demonstrated through suppressing somatic expansion by
crossing HTT knock in mice with Ogg1–/– mice, lacking
the DNA cleaving 7,8-dihydro-8-oxo-guanine (8-oxo-G)
glycosylase.16 Notably, the single most significant SNP in
the present study, rs3512, is in the 30UTR of FAN1,
which has DNA endo/exonuclease activity. Larger CAG
repeats are associated with more-severe pathology and
earlier disease onset in affected patients; therefore,
somatic expansion provides a plausible mechanism by
which the genetic variation we identify here could alter
AAO of polyglutamine diseases (Fig 1). Additional conse-
quences of impaired DNA repair cannot be discarded
though (Fig 1A), and these may also be implicated in a
wider range of neurodegenerative diseases, including sev-
eral ataxic syndromes.33,34
TABLE 4. Individual SNPs Showing Significant Associations With the Age at Onset in Polyglutamine Diseases
SNP Gene Disease Group Two-Sided p Value Same Direction
as GeM-HD?
Significant After Bonferroni for 22 SNPs and 8 Disease Groupings (p < 2.84 3 10–4)
rs3512 FAN1 All (HD1SCAs) 1.52 3 10–5 Yes
rs1805323 PMS2 All (HD1SCAs) 3.14 3 10–5 Yes
rs3512 FAN1 All SCAs 2.22 3 10–4 Yes
Significant After Bonferroni for 22 SNPs (p < 2.27 3 10–3)
rs1805323 PMS2 HD 3.14 3 10–4 Yes
rs1805323 PMS2 SCA1 1.67 3 10–3 Yes
rs1037699 RRM2B SCA6 4.86 3 10–4 Yes
rs1037700 RRM2B SCA6 5.47 3 10–4 Yes
rs5893603 RRM2B SCA6 2.13 3 10–3 Yes
HD 5 Huntington’s disease; SCA 5 spinocerebellar ataxia.
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There are several issues likely to have reduced the
power of our study. The sample sizes for many of the
SCAs were relatively small, and despite modeling the
relationship of age of onset to CAG length separately for
each disease, there is likely to be heterogeneity between
diseases in this and potentially other respects that we
have not been able to consider. We could not account
for interruptions of pure CAG repeat tracts, which may
stabilize repeat instability35; thus, our power to detect
any effects mediated by somatic instability may have
been reduced. Nevertheless, we have shown that DNA
repair genes as a group significantly modify AAO in the
polyglutamine diseases taken together, in HD, in all
SCAs, SCA2, and SCA6. Additionally, we have identified
potential modifier SNPs in HD, SCA1, and SCA6
(Table 4 and Supplementary Table 4). The effects of
these SNPs on AAO are quite small, and it would be
worth repeating the analysis with larger samples and
more SNPs as the predictive power of such polygenic
risk scores increases as sample size and number of var-
iants genotyped increase.36–38
By suggesting common mechanisms for polyglut-
amine diseases, our findings offer novel therapeutic
opportunities in multiple diseases along with the poten-
tial to improve clinical trial design by stratifying subject
variability. Molecules targeting DNA repair have been
FIGURE 1: Potential mechanisms through which variants in DNA repair genes identified in this study might lead to pathogene-
sis in polyglutamine diseases. (A) Overview of possible consequences of inappropriate function of DNA repair pathways in
neurons. (B) Potential somatic expansion mechanism of the CAG repeats in polyglutamine diseases attributed to variation in
genes encoding DNA repair proteins. The accessibility of repetitive DNA sequences during replication, transcription, etc.,
allows the formation of secondary DNA structures: SNPs in genes encoding DNA repair proteins may alter the kinetics or
activity of DNA repair complexes (rc bobble). After endonuclease activity on the opposite strand (nick indicated by the thick
arrow below), such impaired repair may lead to further expansion of the repeat tracts by consequent gap-filling synthesis by
DNA polymerase (pol bobble). SNPs 5 single-nucleotide polymorphisms. [Color figure can be viewed in the online issue, which
is available at www.annalsofneurology.org.]
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developed and are used in the clinic to treat cancers,39,40
and such therapeutics, along with others in development,
may prove useful in some or all of the polyglutamine dis-
eases. Furthermore, these shared mechanisms may extend
to diseases associated with non-CAG and nontranslated
repeats, most likely in those that show somatic
instability.
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